Grace Therapeutics (GRCE)

• Market cap: $48.4M
• 1 day: 1.92%
• 5 days: 0.63%
• 1 month: 7.05%
• 3 months: 7.41%
• 6 months: 22.22%
• Year to date: -20.25%
• 1 year: 2.9%
• 5 years: -64.28%
• 10 years: -97.06%
• Sector: Healthcare
• Industry: Biotechnology

About: Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.

Employees: 6